Abionyx Pharma (CHIX:ABNXP) 9-Day RSI: N/A (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ABNXP Abionyx Pharma CHIX:ABNXP
24 GF Score
Price €1.73
GF Value €0.75
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-07-22), Abionyx Pharma's 9-Day RSI is N/A.

The industry rank for Abionyx Pharma's 9-Day RSI or its related term are showing as below:

CHIX:ABNXp's 9-Day RSI is not ranked *
in the Biotechnology industry.
Industry Median: 44.48
* Ranked among companies with meaningful 9-Day RSI only.

Abionyx Pharma  (CHIX:ABNXp) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Abionyx Pharma 9-Day RSI Related Terms


CHIX:ABNXP vs VRTX, REGN, ALNY: 9-Day RSI Comparison

For the Biotechnology subindustry, Abionyx Pharma's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abionyx Pharma 9-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's 9-Day RSI falls into.


CHIX:ABNXP
24GF Score
Abionyx Pharma CHIX:ABNXP
9-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abionyx Pharma  (CHIX:ABNXp) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Abionyx Pharma (CHIX:ABNXP) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €1.73 is trading 130.9% above its estimated GF Value™ of €0.75.

Key valuation signals for CHIX:ABNXP:

  • 9-Day RSI: N/A
  • GF Value™: €0.75 vs. price of €1.73 (130.9% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the CHIX:ABNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abionyx Pharma Business Description

Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
24GF Score

Get the complete analysis for CHIX:ABNXP

9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.73
Price
€0.75
GF Value